Table 1.
Site‐specific and the overall estimates of nonadherence to antiepileptic drugs
| Site | Agincourt | Ifakara | Iganga‐Maguye | Kilifi | Kintampo | Overall unpooled nonadherence | Partially pooled nonadherencea |
|---|---|---|---|---|---|---|---|
| Self‐reported nonadherence | 73/157 (46.5%) | 123/264 (46.6%) | 89/113 (78.8%) | 252/502 (50.2%) | 234/267 (87.6%) | 771/1,303 (59.2%) | 65.1% (95% CI 45.0–79.5%) |
| Detectable levels nonadherence | 100/157 (63.7%) | 162/264 (61.4%) | 77/113 (68.1%) | 313/502 (62.4%) | 169/267 (63.3%) | 821/1,303 (63.0%) | 63.1% (60.5–65.6%) |
| Optimal levels nonadherence | 116/1,527 (73.9%) | 192/264 (72.7%) | 102/113(90.3%) | 411/502 (81.9%) | 204/267 (76.4%) | 1,025/1,303 (78.7%) | 79.1% (73.3–84.3%) |
| Sensitivity % (95% CI)b | 58.0 (47.7–67.8) | 67.3 (59.5–74.4) | 84.4 (74.4–91.7) | 77.3 (72.3–82.8) | 91.1 (85.8–94.9) | 76.5 (73.4–79.4) | – |
| Specificity % (95% CI)c | 73.7 (60.3–84.5) | 86.3 (78.0–92.3) | 33.3 (18.6–51.0) | 94.7 (90.5–97.4) | 18.4 (11.3–27.5) | 70.3 (66.0–74.4) | – |
CI, confidence interval.
a
Overall magnitude of nonadherence to antiepileptic drugs for the five sites and the corresponding confidence intervals obtained from a multilevel model that incorporated between‐sites variation.
b
Sensitivity of the self‐reported nonadherence to antiepileptic drugs versus detectable levels.
c
Specificity of the self‐reported nonadherence to antiepileptic drugs versus detectable levels.